ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.34T | 23.58% |
2JNJ | JOHNSON & JOHNSON | Healthcare | $682.52B | 11.99% |
3ABBV | ABBVIE INC | Healthcare | $520.47B | 9.14% |
4MRK | MERCK & CO INC | Healthcare | $362.27B | 6.36% |
5AMGN | AMGEN INC | Healthcare | $252.64B | 4.44% |
6GILD | GILEAD SCIENCES INC | Healthcare | $208.31B | 3.66% |
7ABT | ABBOTT LABORATORIES | Healthcare | $185.75B | 3.26% |
8PFE | PFIZER INC | Healthcare | $164.33B | 2.89% |
9ISRG | INTUITIVE SURGICAL INC | Healthcare | $152.49B | 2.68% |
10VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $137.57B | 2.42% |
11BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $127.39B | 2.24% |
12NEM | NEWMONT CORP | Basic Materials | $117.05B | 2.06% |
13REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $98.40B | 1.73% |
14MRNA | MODERNA INC | Healthcare | $93.61B | 1.64% |
15BDX | BECTON DICKINSON & CO | Healthcare | $58.76B | 1.03% |
16IDXX | IDEXX LABORATORIES INC | Healthcare | $54.99B | 0.97% |
17TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $50.93B | 0.89% |
18ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 0.83% |
19RPRX | ROYALTY PHARMA PLC | Healthcare | $39.56B | 0.69% |
20RVMD | REVOLUTION MEDICINES INC | Healthcare | $38.14B | 0.67% |
21BIIB | BIOGEN INC | Healthcare | $37.03B | 0.65% |
22ZTS | ZOETIS INC | Healthcare | $33.71B | 0.59% |
23DXCM | DEXCOM INC | Healthcare | $30.35B | 0.53% |
24ROIV | ROIVANT SCIENCES LTD | Healthcare | $28.98B | 0.51% |
25INSM | INSMED INC | Healthcare | $25.90B | 0.45% |
26UTHR | UNITED THERAPEUTICS CORP | Healthcare | $25.27B | 0.44% |
27VTRS | VIATRIS INC | Healthcare | $23.70B | 0.42% |
28SW | SMURFIT WESTROCK PLC | Consumer Cyclical | $22.65B | 0.40% |
29PKG | PACKAGING CORP OF AMERICA | Consumer Cyclical | $22.33B | 0.39% |
30ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $20.98B | 0.37% |
31NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.15B | 0.30% |
32BALL | BALL CORP | Consumer Cyclical | $16.90B | 0.30% |
33JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.43B | 0.27% |
34BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.23B | 0.27% |
35SOLV | SOLVENTUM CORP | Healthcare | $15.07B | 0.26% |
36CDE | COEUR MINING INC | Basic Materials | $14.61B | 0.26% |
37GKOS | GLAUKOS CORP | Healthcare | $14.56B | 0.26% |
38ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $13.25B | 0.23% |
39CCK | CROWN HOLDINGS INC | Consumer Cyclical | $13.02B | 0.23% |
40SMMT | SUMMIT THERAPEUTICS INC | Healthcare | $12.06B | 0.21% |
41COO | COOPER COMPANIES INC | Healthcare | $11.83B | 0.21% |
42HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 0.20% |
43TECH | BIO-TECHNE CORP | Healthcare | $11.44B | 0.20% |
44BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $10.98B | 0.19% |
45KYMR | KYMERA THERAPEUTICS INC | Healthcare | $10.86B | 0.19% |
46RGEN | REPLIGEN CORP | Healthcare | $10.64B | 0.19% |
47PCVX | VAXCYTE INC | Healthcare | $10.24B | 0.18% |
48MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $9.88B | 0.17% |
49TGTX | TG THERAPEUTICS INC | Healthcare | $9.76B | 0.17% |
50PRAX | PRAXIS PRECISION MEDICINES INC | Healthcare | $9.08B | 0.16% |
51KRYS | KRYSTAL BIOTECH INC | Healthcare | $9.06B | 0.16% |
52PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $8.77B | 0.15% |
53CORT | CORCEPT THERAPEUTICS INC | Healthcare | $8.07B | 0.14% |
54ALKS | ALKERMES PLC | Healthcare | $7.89B | 0.14% |
55CYTK | CYTOKINETICS INC | Healthcare | $7.82B | 0.14% |
56AXSM | AXSOME THERAPEUTICS INC | Healthcare | $7.59B | 0.13% |
57KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $7.56B | 0.13% |
58AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $7.56B | 0.13% |
59BLCO | BAUSCH & LOMB CORP | Healthcare | $7.56B | 0.13% |
60IMVT | IMMUNOVANT INC | Healthcare | $7.25B | 0.13% |
61TWST | TWIST BIOSCIENCE CORP | Healthcare | $7.16B | 0.13% |
62ORKA | ORUKA THERAPEUTICS INC | Healthcare | $7.12B | 0.13% |
63KOD | KODIAK SCIENCES INC | Healthcare | $6.80B | 0.12% |
64MSA | MSA SAFETY INC | Industrials | $6.73B | 0.12% |
65RIOT | RIOT PLATFORMS INC | Financial Services | $6.69B | 0.12% |
66ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $6.66B | 0.12% |
67LNTH | LANTHEUS HOLDINGS INC | Healthcare | $6.62B | 0.12% |
68IBRX | IMMUNITYBIO INC | Healthcare | $6.46B | 0.11% |
69LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.33B | 0.11% |
70CGON | CG ONCOLOGY INC | Healthcare | $6.27B | 0.11% |
71MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $6.09B | 0.11% |
72TFX | TELEFLEX INC | Healthcare | $6.07B | 0.11% |
73ERAS | ERASCA INC | Healthcare | $5.52B | 0.10% |
74PTCT | PTC THERAPEUTICS INC | Healthcare | $5.29B | 0.09% |
75SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $5.27B | 0.09% |
76DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.21B | 0.09% |
77COGT | COGENT BIOSCIENCES INC | Healthcare | $5.07B | 0.09% |
78EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $5.02B | 0.09% |
79TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $4.95B | 0.09% |
80SON | SONOCO PRODUCTS CO | Consumer Cyclical | $4.81B | 0.08% |
81ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $4.77B | 0.08% |
82IONS | IONIS PHARMACEUTICALS INC | Healthcare | $4.55B | 0.08% |
83ICUI | ICU MEDICAL INC | Healthcare | $4.43B | 0.08% |
84SLGN | SILGAN HOLDINGS INC | Consumer Cyclical | $4.30B | 0.08% |
85TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.21B | 0.07% |
86CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.13B | 0.07% |
87XENE | XENON PHARMACEUTICALS INC | Healthcare | $4.03B | 0.07% |
88RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.99B | 0.07% |
89AMLX | AMYLYX PHARMACEUTICALS INC | Healthcare | $3.84B | 0.07% |
90ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $3.80B | 0.07% |
91TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $3.79B | 0.07% |
92IRON | DISC MEDICINE INC | Healthcare | $3.79B | 0.07% |
93OGN | ORGANON & CO | Healthcare | $3.65B | 0.06% |
94ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.56B | 0.06% |
95IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $3.53B | 0.06% |
96ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.48B | 0.06% |
97GPK | GRAPHIC PACKAGING HOLDING CO | Consumer Cyclical | $3.19B | 0.06% |
98DYN | DYNE THERAPEUTICS INC | Healthcare | $3.19B | 0.06% |
99ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $3.14B | 0.06% |
100BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 0.05% |
101IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.04B | 0.05% |
102XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $3.04B | 0.05% |
103DNLI | DENALI THERAPEUTICS INC | Healthcare | $3.03B | 0.05% |
104ADMA | ADMA BIOLOGICS INC | Healthcare | $2.94B | 0.05% |
105VCEL | VERICEL CORP | Healthcare | $2.93B | 0.05% |
106XNCR | XENCOR INC | Healthcare | $2.86B | 0.05% |
107MBX | MBX BIOSCIENCES INC | Healthcare | $2.71B | 0.05% |
108RCUS | ARCUS BIOSCIENCES INC | Healthcare | $2.56B | 0.04% |
109BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.49B | 0.04% |
110NEOG | NEOGEN CORP | Healthcare | $2.44B | 0.04% |
111UFPT | UFP TECHNOLOGIES INC | Healthcare | $2.37B | 0.04% |
112SDGR | SCHRODINGER INC | Healthcare | $2.32B | 0.04% |
113PRGO | PERRIGO CO PLC | Healthcare | $2.25B | 0.04% |
114CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.24B | 0.04% |
115PPTA | PERPETUA RESOURCES CORP | Basic Materials | $2.23B | 0.04% |
116IMNM | IMMUNOME INC | Healthcare | $2.21B | 0.04% |
117AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.17B | 0.04% |
118PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.15B | 0.04% |
119BHVN | BIOHAVEN LTD | Healthcare | $2.13B | 0.04% |
120SUPN1 | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.11B | 0.04% |
121VERA | VERA THERAPEUTICS INC | Healthcare | $2.10B | 0.04% |
122REPL | REPLIMUNE GROUP INC | Healthcare | $2.08B | 0.04% |
123VIR | VIR BIOTECHNOLOGY INC | Healthcare | $2.08B | 0.04% |
124MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $2.00B | 0.04% |
125SEPN | SEPTERNA INC | Healthcare | $1.99B | 0.03% |
126HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.98B | 0.03% |
127BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $1.98B | 0.03% |
128MAZE | MAZE THERAPEUTICS INC | Healthcare | $1.97B | 0.03% |
129TRVI | TREVI THERAPEUTICS INC | Healthcare | $1.94B | 0.03% |
130AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $1.90B | 0.03% |
131ZBIO | ZENAS BIOPHARMA INC | Healthcare | $1.87B | 0.03% |
132ZYME | ZYMEWORKS INC | Healthcare | $1.83B | 0.03% |
133ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.77B | 0.03% |
134QURE | UNIQURE NV | Healthcare | $1.73B | 0.03% |
135SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.03% |
136STOK | STOKE THERAPEUTICS INC | Healthcare | $1.71B | 0.03% |
137NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.03% |
138RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $1.66B | 0.03% |
139ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.62B | 0.03% |
140HYMC | HYCROFT MINING HOLDING CORP | Basic Materials | $1.58B | 0.03% |
141IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.57B | 0.03% |
142RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $1.53B | 0.03% |
143CNMD | CONMED CORP | Healthcare | $1.50B | 0.03% |
144NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.48B | 0.03% |
145PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.46B | 0.03% |
146NVAX | NOVAVAX INC | Healthcare | $1.45B | 0.03% |
147PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.03% |
148ANAB | ANAPTYSBIO INC | Healthcare | $1.43B | 0.03% |
149GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $1.42B | 0.02% |
150OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.38B | 0.02% |
151NVCR | NOVOCURE LTD | Healthcare | $1.37B | 0.02% |
152TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.37B | 0.02% |
153INVA | INNOVIVA INC | Healthcare | $1.35B | 0.02% |
154STAA | STAAR SURGICAL CO | Healthcare | $1.34B | 0.02% |
155OMER | OMEROS CORP | Healthcare | $1.30B | 0.02% |
156URGN | UROGEN PHARMA LTD | Healthcare | $1.29B | 0.02% |
157INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.29B | 0.02% |
158NKTR | NEKTAR THERAPEUTICS | Healthcare | $1.27B | 0.02% |
159AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $1.23B | 0.02% |
160ANRO | ALTO NEUROSCIENCE INC | Healthcare | $1.23B | 0.02% |
161VOR | VOR BIOPHARMA INC | Healthcare | $1.19B | 0.02% |
162IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.12B | 0.02% |
163MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.10B | 0.02% |
164IRMD | IRADIMED CORP | Healthcare | $1.09B | 0.02% |
165HROW | HARROW INC | Healthcare | $1.06B | 0.02% |
166CBLL | CERIBELL INC | Healthcare | $1.02B | 0.02% |
167CYRX | CRYOPORT INC | Industrials | $1.02B | 0.02% |
168JBIO | JADE BIOSCIENCES INC | Healthcare | $1.01B | 0.02% |
169BVS | BIOVENTUS INC | Healthcare | $915M | 0.02% |
170CRVS | CORVUS PHARMACEUTICALS INC | Healthcare | $896M | 0.02% |
171ORIC | ORIC PHARMACEUTICALS INC | Healthcare | $881M | 0.02% |
172SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $859M | 0.02% |
173KIDS | ORTHOPEDIATRICS CORP | Healthcare | $851M | 0.01% |
174MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $844M | 0.01% |
175GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $796M | 0.01% |
176ALMS | ALUMIS INC | Healthcare | $793M | 0.01% |
177SLDB | SOLID BIOSCIENCES INC | Healthcare | $781M | 0.01% |
178COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $775M | 0.01% |
179AURA | AURA BIOSCIENCES INC | Healthcare | $740M | 0.01% |
180MUX | MCEWEN INC | Basic Materials | $736M | 0.01% |
181QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.01% |
182JANX | JANUX THERAPEUTICS INC | Healthcare | $703M | 0.01% |
183KURA | KURA ONCOLOGY INC | Healthcare | $683M | 0.01% |
184DSGN | DESIGN THERAPEUTICS INC | Healthcare | $678M | 0.01% |
185BCAX | BICARA THERAPEUTICS INC | Healthcare | $671M | 0.01% |
186FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $669M | 0.01% |
187DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.01% |
188CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $662M | 0.01% |
189CADL | CANDEL THERAPEUTICS INC | Healthcare | $642M | 0.01% |
190CLYM | CLIMB BIO INC | Healthcare | $639M | 0.01% |
191SGHT | SIGHT SCIENCES INC | Healthcare | $611M | 0.01% |
192SRZN | SURROZEN INC | Healthcare | $604M | 0.01% |
193CAPR | CAPRICOR THERAPEUTICS INC | Healthcare | $595M | 0.01% |
194IMMX | IMMIX BIOPHARMA INC | Healthcare | $577M | 0.01% |
195MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.01% |
196CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 0.01% |
197RGNX | REGENXBIO INC | Healthcare | $531M | 0.01% |
198TKNO | ALPHA TEKNOVA INC | Healthcare | $522M | 0.01% |
199RCEL | AVITA MEDICAL INC | Healthcare | $509M | 0.01% |
200PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $506M | 0.01% |
201ANGO | ANGIODYNAMICS INC | Healthcare | $504M | 0.01% |
202DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $503M | 0.01% |
203NGNE | NEUROGENE INC | Healthcare | $495M | 0.01% |
204EOLS | EVOLUS INC | Healthcare | $475M | 0.01% |
205ARVN | ARVINAS INC | Healthcare | $450M | 0.01% |
206CTGO | CONTANGO SILVER & GOLD INC | Basic Materials | $437M | 0.01% |
207PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.01% |
208TECX | TECTONIC THERAPEUTIC INC | Healthcare | $420M | 0.01% |
209PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.01% |
210ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $411M | 0.01% |
211LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $385M | 0.01% |
212CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $384M | 0.01% |
213TMCI | TREACE MEDICAL CONCEPTS INC | Healthcare | $350M | 0.01% |
214PEPG | PEPGEN INC | Healthcare | $349M | 0.01% |
215ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $326M | 0.01% |
216BNTC | BENITEC BIOPHARMA INC | Healthcare | $317M | 0.01% |
217KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $311M | 0.01% |
218AGEN | AGENUS INC | Healthcare | $311M | 0.01% |
219EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.01% |
220IDR | IDAHO STRATEGIC RESOURCES INC | Basic Materials | $300M | 0.01% |
221SMTI | SANARA MEDTECH INC | Healthcare | $299M | 0.01% |
222FTH | FAETH THERAPEUTICS INC | Healthcare | $275M | 0.00% |
223BIOA | BIOAGE LABS INC | Healthcare | $260M | 0.00% |
224ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.00% |
225USNA | USANA HEALTH SCIENCES INC | Consumer Defensive | $235M | 0.00% |
226DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.00% |
227PDEX | PRO DEX INC | Healthcare | $216M | 0.00% |
228TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.00% |
229KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.00% |
230KRRO | KORRO BIO INC | Healthcare | $196M | 0.00% |
231RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.00% |
232ACOG | ALPHA COGNITION INC | Healthcare | $186M | 0.00% |
233ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.00% |
234NATR | NATURES SUNSHINE PRODUCTS INC | Consumer Defensive | $178M | 0.00% |
235STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.00% |
236INGN | INOGEN INC | Healthcare | $146M | 0.00% |
237CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.00% |
238IMUX | IMMUNIC INC | Healthcare | $106M | 0.00% |
239CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $99M | 0.00% |
240ICCC | IMMUCELL CORP | Healthcare | $93M | 0.00% |
241ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.00% |
242FTLF | FITLIFE BRANDS INC | Consumer Defensive | $78M | 0.00% |
243NTRB | NUTRIBAND INC | Healthcare | $73M | 0.00% |
244GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.00% |
245APT | ALPHA PRO TECH LTD | Industrials | $64M | 0.00% |
246LFVN | LIFEVANTAGE CORP | Consumer Defensive | $64M | 0.00% |
247XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.00% |
248POCI | PRECISION OPTICS CORPORATION INC | Healthcare | $55M | 0.00% |
249COCH | ENVOY MEDICAL INC | Healthcare | $53M | 0.00% |
250YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $5.69T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,140-name universe at November 2026. Rows: Large ≥ $5.3B, Small < $832M. Columns: Value ≥ 0.62, Growth < 0.33 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 89% toward Growth. +6% unclassified (36 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 250 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T063725 rates=20261113T063725
Measured on the 2026-11 formation date across 250 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 17%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 15.2% | 13.0% |
| 3 yearsp.a. | 19.5% | -4.6% |
| 5 yearsp.a. | 7.6% | -4.6% |
| 10 yearsp.a. | 10.6% | -3.2% |
| Since inceptionp.a. | 8.3% | 1.6% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 11.1% | 10.0% |
| 2025 | 50.8% | 27.8% |
| 2024 | -4.0% | -37.8% |
| 2023 | -1.7% | -13.9% |
| 2022 | -8.1% | 5.9% |
| 2021 | 21.2% | 8.8% |
| 2020 | 18.3% | 3.3% |
| 2019 | 30.7% | -2.8% |
| 2018 | -17.0% | -16.1% |
| 2017 | 19.6% | -1.8% |
| 2016 | -2.9% | -12.0% |
| 2015 | 1.5% | 13.9% |
| 2014 | 18.3% | 11.7% |
| 2013 | 34.0% | -6.1% |
| 2012 | 12.6% | -11.0% |
| 2011 | -3.4% | -5.7% |
| 2010 | 11.6% | -3.9% |
| 2009 | 26.9% | 2.4% |
| 2008 | -31.6% | 36.1% |
| 2007 | -8.8% | -15.8% |
| 2006 | 17.3% | 0.2% |
| 2005 | 10.3% | 3.9% |
| 2004 | 5.1% | -3.7% |
| 2003 | 36.1% | -0.3% |
| 2002 | -25.6% | 5.6% |
| 2001 | 0.6% | 41.6% |
| 2000 | 19.9% | 52.7% |
| 1999 | 37.3% | -4.0% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Investment Discipline Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a Investment Discipline signal and holds the top decile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.